For citations:
Shipaeva E.V., Filon O.V., Zintchenko A.V., Shipunov G.A., Dmitrieva A.A., Lemak M.S., Grishin S.A., Trofimets E.I., Kryshen K.L., Kozlovskaya L.I., Lunin A.S., Apolokhov V.D., Barbashov S.F., Lavrovsky Ya.V., Samsonov M.Yu. Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19. Biological Products. Prevention, Diagnosis, Treatment. 2022;22(4):414-434. (In Russ.) https://doi.org/10.30895/2221-996X-2022-22-4-414-434
Email this article 